Matthew P. Goetz, MD

Articles

Dr. Goetz on the Use of ctDNA in the MONARCH-3 Trial in HR+/HER2- Breast Cancer

January 9th 2020

Matthew P. Goetz, MD, Mayo Clinic, discusses the use of circulating tumor DNA in the phase III MONARCH-3 trial in hormone receptor–positive, HER2-negative breast cancer.

Dr. Goetz on Adverse Events With Aromatase Inhibitors in Breast Cancer

September 25th 2019

Matthew P. Goetz, MD, discusses adverse events associated with aromatase inhibitors.

Dr. Goetz on Treatment Beyond Progression on CDK4/6 Inhibitors in HR+ Breast Cancer

August 23rd 2019

Matthew P. Goetz, MD, consultant, Division of Medical Oncology, Department of Oncology, Mayo Clinic, discusses treatment beyond progression on CDK4/6 inhibitors in hormone receptor (HR)-positive breast cancer.

Dr. Goetz on Treatment Challenges for ESR1-Mutant Breast Cancer

August 16th 2019

Matthew P. Goetz, MD, consultant, Division of Medical Oncology, Department of Oncology, Mayo Clinic, discusses the treatment landscape of estrogen receptor (ER)–positive breast cancer and advances made within the last 5 years.

Dr. Goetz on Treatment of Metastatic HR+ Breast Cancer

February 28th 2019

Matthew P. Goetz, MD, chair of the Breast Cancer Disease-Oriented Group and co-leader of the Women’s Cancer Center at the Mayo Clinic, discusses the treatment landscape for patients with metastatic hormone receptor–positive breast cancer.

Dr. Goetz on Survival Data With CDK4/6 Inhibitors in Breast Cancer

January 23rd 2019

Matthew P. Goetz, MD, chair of the Breast Cancer Disease-Oriented Group and co-leader of the Women’s Cancer Center at the Mayo Clinic, discusses survival data with CDK4/6 inhibitors in patients with hormone receptor-positive breast cancer.

Dr. Goetz on the MONARCH Trials for Breast Cancer

January 30th 2018

Matthew P. Goetz, MD, professor of oncology and pharmacology, Division of Medical Oncology, Department of Oncology, Mayo Clinic, discusses the MONARCH trials for patients with breast cancer.